The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD.

ABSTRACT:

Background and hypothesis

The only therapy to ameliorate disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) is tolvaptan, a vasopressin V2 receptor antagonist. Real-life data on long-term tolvaptan treatment are sparse and limited by restricted follow-up, small patient groups or lack of a control group. We studied the long-term effect of tolvaptan on kidney function and kidney growth in real-life patients and controls. Moreover, we investigated determinants of long-term treatment efficacy.

Methods

Data from the prospective DIPAK cohort and retrospective OBSERVA cohort were pooled. estimated glomerular filtration rate (eGFR) was measured at least yearly and total kidney volume (TKV) at least every 3 years. Treatment effects from the star

SUBMITTER: Geertsema P 

PROVIDER: S-EPMC12451683 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature